98%
921
2 minutes
20
Background: Women who drink are more vulnerable than men to many of the consequences of alcohol use, including alcohol-related cancers, cardiovascular disease, liver cirrhosis, and immune system dysfunction. Acute alcohol triggers neuroimmune cells including microglia-the brain's resident immune cells. Excessive activation can contribute to neuronal dysfunction and alcohol-induced neurodegeneration. Women have a greater vulnerability to alcohol-induced neurodegeneration; thus, there is a critical need to examine sex differences in neuroimmune mechanisms that underlie alcohol use disorder (AUD) to inform novel treatment strategies for women.
Methods: A total of 41 individuals with mild-to-moderate AUD (20 women) and 37 sex-matched control individuals completed a positron emission tomography brain imaging scan with the radiotracer [C]PBR28, which binds to the 18-kDa TSPO, a microglial marker. Volume of distribution was estimated regionally in the cerebellum, hippocampus, striatum, and frontal cortex as a measure of TSPO availability. Neurocognitive function was also assessed.
Results: People with versus without AUD had significantly lower TSPO availability in all brain regions. Women (but not men) with AUD had significantly lower TSPO availability (average of 21%) in all 4 regions (p = .022) compared with sex-matched control participants. Women with versus without AUD performed worse on executive function (p = .020). Lower hippocampal (p = .059) and cerebellar (p = .097) TSPO availability were trendingly related to more errors on the executive function task in women with AUD.
Conclusions: This study showed lower TSPO levels in people with mild-to-moderate AUD versus control participants and demonstrated that the deficit was significantly greater in women than men with AUD. This suggests that women with AUD may particularly benefit from novel neuroimmune-modulating treatments for AUD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353993 | PMC |
http://dx.doi.org/10.1016/j.biopsych.2025.05.012 | DOI Listing |
Mol Psychiatry
August 2025
Department of Psychiatry, Hamamatsu University School of Medicine, Hamamatsu, Japan.
The α7 nicotinic acetylcholine receptor (nAChR) plays a crucial role in cognitive function, and its dysfunction has been proposed as a primary pathophysiological factor in schizophrenia. Although the α7 nAChR is expressed in both neuronal and activated glial cells, its association with activated glia and its role in the pathophysiology of schizophrenia remain uncertain. Therefore, we investigated α7 nAChR availability and activated glia evaluated with 18 kDa translocator protein (TSPO) levels in individuals with schizophrenia, and further examined their association and relationships to cognitive impairment.
View Article and Find Full Text PDFEJNMMI Rep
August 2025
Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Background: Imaging plays a crucial role in the clinical management of patients with inflammatory diseases, both for diagnosis and in evaluating treatment response. 2-deoxy-2-[18F]-fluoro-D-glucose ([F]FDG) positron emission tomography/computed tomography (PET/CT) is a non-invasive imaging technique that is gaining prominence in the study of various infectious and inflammatory diseases. Advances in PET imaging technology, along with the development of new radiopharmaceuticals, have the potential to enhance the diagnostic accuracy of imaging in the evaluation of inflammation, allowing for the tracking of disease activity through mechanisms distinct from FDG.
View Article and Find Full Text PDFJ Neuroinflammation
August 2025
Turku PET Centre, University of Turku, Turku University Hospital and Åbo Akademi University, Turku, Finland.
In multiple sclerosis (MS), accumulation of disability is driven by CNS-compartmentalized inflammation. This inflammatory process involves activated microglia and astrocytes, which contribute to neuroaxonal damage which in turn accelerates disease progression. Activated glial cells express 18-kDa translocator protein (TSPO), and TSPO-binding radioligands and positron emission tomography (PET) imaging can be used to quantitate glial activation in vivo.
View Article and Find Full Text PDFTher Adv Neurol Disord
July 2025
Turku PET Centre, University of Turku, Åbo Akademi University, Turku University Hospital, Turku, Finland.
Background: Serum glial fibrillary acidic protein (sGFAP) is a promising biomarker for multiple sclerosis (MS) disease progression. Elevated sGFAP levels are considered to reflect ongoing astrocyte-related pathology in the central nervous system.
Objectives: To study whether sGFAP levels associate with 18 kDa translocator protein (TSPO) availability in MS brain.
Semin Nucl Med
July 2025
Division of Nuclear Medicine, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP), Institute of Radiology, Sao Paulo, Brazil; Nuclear Medicine and PET/CT section, Centro de Diagnósticos, Hospital Sirio-Libanês, Sao Paulo, Brazil. Electronic address: arturcoutinh
Positron emission tomography (PET) has emerged as a pivotal imaging modality in the investigation of psychiatric disorders, enabling in vivo assessment of regional cerebral metabolism, neurotransmitter dynamics, receptor binding, synaptic density, and neuroinflammation. This comprehensive review synthesizes current evidence on the utility of PET imaging in elucidating the pathophysiology of major psychiatric conditions-including schizophrenia, mood disorders, autism spectrum disorder, attention-deficit/hyperactivity disorder, and addiction and its potential in clinical decision-making. F-FDG-PET has consistently demonstrated regional metabolic abnormalities, most notably prefrontal hypometabolism in schizophrenia and major depressive disorder, with implications for negative symptomatology, cognitive dysfunction, and treatment resistance.
View Article and Find Full Text PDF